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Abstract
Forty-one patients with small cell carcinoma of the lung were treated with a four-drug com-
bination of cyclophosphamide, vincristine, methotrexate, and procarbazine. The response rate
was 68% (28 responded among 41 patients), with 10 complete responses (24%) and 18 partial re-
sponses (44%). The median survival time from the initiation of chemotherapy was 11 months for
patients with limited disease and 8 months for those with extensive disease. Patients who achieved
complete response survived significantly longer than those who did not; the median survival time
for complete responders was 14.5 months, compared to 8.5 months for partial responders and 6
months for non-responders. Myelosuppressive toxicity remained within acceptable limits, with
5% incidence of leukocytopenia (less than 1,000/microliter) and 7% incidence of thrombocytope-
nia (less than 50,000/microliter) following the first course of the regimen.
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